Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Multiple Cancer Types

Leukemia, Pediatric Leukemia, Pediatrics
III
Zarnegar-Lumley, Sara
NCT04293562
COGAAML1831

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: